Vindesine sulfate
Modify Date: 2024-01-02 23:38:22
Vindesine sulfate structure
|
Common Name | Vindesine sulfate | ||
|---|---|---|---|---|
| CAS Number | 59917-39-4 | Molecular Weight | 852.00 | |
| Density | 1.41 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C43H57N5O11S | Melting Point | >250ºC | |
| MSDS | N/A | Flash Point | N/A | |
Use of Vindesine sulfateVindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 µM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo[1]. |
| Name | vindesine sulfate |
|---|---|
| Synonym | More Synonyms |
| Description | Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 µM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Vindesine sulfate inhibits L-cells growth and shows about 25% inhibition at 40 nM[1]. |
| References |
| Density | 1.41 g/cm3 |
|---|---|
| Melting Point | >250ºC |
| Molecular Formula | C43H57N5O11S |
| Molecular Weight | 852.00 |
| Exact Mass | 851.377502 |
| PSA | 247.80000 |
| LogP | 3.80150 |
| Storage condition | 2-8°C |
| Water Solubility | deionized water: ≥50mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| Hazard Codes | Xn: Harmful; |
|---|---|
| Risk Phrases | R40 |
| Safety Phrases | 26-36 |
| RIDADR | UN 1544 |
| RTECS | YY8090000 |
| Packaging Group | II |
| Hazard Class | 6.1(a) |
| HS Code | 2942000000 |
| HS Code | 2942000000 |
|---|
|
Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study
J. Pharm. Biomed. Anal. 96 , 31-6, (2014) Mean plasma concentration–time profiles of intravenous injection of 3mg Vindesine Sulfate for Injection to 100 unrelated Chinese Han subjects with hematological malignant disorders. |
|
|
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
J. Clin. Oncol. 32(35) , 3996-4003, (2014) To determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma (DLBCL) and low-intermediate risk a... |
|
|
Reovirus cell entry requires functional microtubules.
MBio 4 , (2013) Mammalian reovirus binds to cell-surface glycans and junctional adhesion molecule A and enters cells by receptor-mediated endocytosis in a process dependent on β1 integrin. Within the endocytic compar... |
| 2H-3,7-Methanoazacycloundecino[5,4-b]indole-9-carboxylic acid, 9-[(2β,3β,4β,5α,12β,19α)-3-(aminocarbonyl)-6,7-didehydro-3,4-dihydroxy-16-methoxy-1-methylaspidospermidin-15-yl]-5-et hyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (5S,7S,9S)-, sulfate (1:1) (salt) |
| methyl (5S,7S,9S)-9-[(2β,3β,4β,5α,12β,19α)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate sulfate (1:1) |
| Vindesine Sulfate Salt |
| 2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylic acid, 9-[(2β,3β,4β,5α,12β,19α)-3-(aminocarbonyl)-6,7-didehydro-3,4-dihydroxy-16-methoxy-1-methylaspidospermidin-15-yl]-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (5S,7S,9S)-, sulfate (1:1) (salt) |
| Vindesine sulphate |
| Methyl (13S,15S,17S)-13-[(2β,3β,4β,5α,12β,19α)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraene-13-carboxylate sulfate (1:1) |